Whipplewood Advisors LLC Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP)

Whipplewood Advisors LLC bought a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) in the fourth quarter, HoldingsChannel reports. The fund bought 4,037 shares of the company’s stock, valued at approximately $159,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new position in CRISPR Therapeutics in the 3rd quarter worth about $40,000. Darwin Wealth Management LLC acquired a new stake in shares of CRISPR Therapeutics in the third quarter valued at about $43,000. Highline Wealth Partners LLC acquired a new stake in shares of CRISPR Therapeutics in the fourth quarter valued at about $39,000. Western Pacific Wealth Management LP increased its stake in shares of CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after buying an additional 500 shares during the period. Finally, Spire Wealth Management increased its stake in shares of CRISPR Therapeutics by 303.7% in the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after buying an additional 1,482 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Down 1.8 %

CRSP stock opened at $43.62 on Friday. CRISPR Therapeutics AG has a twelve month low of $36.52 and a twelve month high of $90.62. The stock’s 50 day moving average is $42.36 and its 200-day moving average is $45.99. The firm has a market capitalization of $3.74 billion, a PE ratio of -9.98 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on CRSP shares. HC Wainwright reissued a “buy” rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Barclays increased their price target on CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 12th. Morgan Stanley increased their price target on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a research note on Friday, February 14th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research note on Thursday, February 13th. Finally, Evercore ISI raised CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and raised their target price for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $74.40.

Insider Activity

In related news, CEO Samarth Kulkarni sold 18,360 shares of the stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the completion of the sale, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at approximately $9,473,037.60. This trade represents a 9.66 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.